Zentalis Doses First Patient in Phase III Azenosertib Trial; Bayer Acquires Perfuse
This edition of Pharmaceutical Executive Daily highlights significant developments in the life sciences sector. Zentalis Pharmaceuticals announced it has dosed the first patient in the Phase III Aspenova clinical trial for Azenosertib, a potential first-in-class oral WEE1 inhibitor. The trial targets patients with Cyclin E1-positive platinum-resistant ovarian cancer and involves collaboration with major oncology groups including the GOG Foundation. In major corporate transactions, Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion to bolster its pipeline in glaucoma and diabetic retinopathy treatments. Separately, Madrigal Pharmaceuticals secured an exclusive global license from Arrowhead Pharmaceuticals for ARO-PNPLA3, a siRNA therapy targeting MASH, with deal values reaching up to $975 million in milestones. Additionally, the briefing features analysis by Brooke Ervin on the challenges of translating real-world evidence into actionable commercial and clinical impacts in urology. Ervin argues that structural failures in data contextualization hinder effective decision-making, requiring more deliberate evidence design. These updates reflect ongoing strategic movements in pharmaceutical acquisitions, clinical advancements in oncology, and critical discussions on healthcare data utilization.
Wire timeline
Zentalis Doses First Patient in Phase III Azenosertib Trial; Bayer Acquires Perfuse
This edition of Pharmaceutical Executive Daily highlights significant developments in the life sciences sector. Zentalis Pharmaceuticals announced it has dosed the first patient in the Phase III Aspenova clinical trial for Azenosertib, a potential first-in-class oral WEE1 inhibitor. The trial targets patients with Cyclin E1-positive platinum-resistant ovarian cancer and involves collaboration with major oncology groups including the GOG Foundation. In major corporate transactions, Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion to bolster its pipeline in glaucoma and diabetic retinopathy treatments. Separately, Madrigal Pharmaceuticals secured an exclusive global license from Arrowhead Pharmaceuticals for ARO-PNPLA3, a siRNA therapy targeting MASH, with deal values reaching up to $975 million in milestones. Additionally, the briefing features analysis by Brooke Ervin on the challenges of translating real-world evidence into actionable commercial and clinical impacts in urology. Ervin argues that structural failures in data contextualization hinder effective decision-making, requiring more deliberate evidence design. These updates reflect ongoing strategic movements in pharmaceutical acquisitions, clinical advancements in oncology, and critical discussions on healthcare data utilization.
PharmExec articles